Management tracks: Genmab, Kintai, Aerie, Oasmia, Sangamo, Ovid, Checkmate, Third Pole, Actimed, IMV, Entasis, Rafael, Evaxion and Arvelle

David Eatwell will retire as CFO and EVP of Genmab A/S (CSE:GMAB; NASDAQ:GMAB) on Feb. 29. The cancer antibody therapy company will promote Anthony Pagano, SVP finance and corporate development, to CFO and EVP, effective March 1, and begin a search for an EVP and COO to expand its executive team.

Kintai Therapeutics Inc. said John Baldoni joined the metabolic and autoimmune disease company as chief technology adviser. He was SVP of R&D at GlaxoSmithKline plc (LSE:GSK; NYSE:GSK)...